

Evgenii A Osmanov

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3864231/publications.pdf>

Version: 2024-02-01

11
papers

685
citations

1478505

6
h-index

1281871

11
g-index

11
all docs

11
docs citations

11
times ranked

1121
citing authors

#	ARTICLE	IF	CITATIONS
1	Bortezomib-Based Therapy for Newly Diagnosed Mantle-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2015, 372, 944-953.	27.0	343
2	Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL. <i>Blood</i> , 2015, 126, 1893-1901.	1.4	117
3	Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2011, 12, 773-784.	10.7	98
4	Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study. <i>Lancet Oncology</i> , The, 2018, 19, 1449-1458.	10.7	93
5	Prespecified Candidate Biomarkers Identify Follicular Lymphoma Patients Who Achieved Longer Progression-Free Survival with Bortezomibâ€“Rituximab Versus Rituximab. <i>Clinical Cancer Research</i> , 2013, 19, 2551-2561.	7.0	16
6	Association between bortezomib dose intensity and overall survival in mantle cell lymphoma patients on frontline VR-CAP in the phase 3 LYM-3002 study. <i>Leukemia and Lymphoma</i> , 2019, 60, 172-179.	1.3	11
7	EXPRESSION OF CANCER-TESTIS GENES PRAME, NY-ESO1, GAGE1, MAGE A3, MAGE A6, MAGE A12, SSX1, SLLP1, PASD1 IN PATIENTS WITH MULTIPLE MYELOMA, THEIR INFLUENCE ON OVERALL SURVIVAL AND RELAPSE RATE. <i>Uspehi Molekularnoj Onkologii</i> , 2018, 5, 62-70.	0.3	2
8	Chronic â€œgraft versus hostâ€•disease after allogeneic hematopoietic stem cell transplantation: basic characteristics, pathogenetic mechanisms, treatment strategies and problems of clinical practice. <i>Russian Journal of Pediatric Hematology and Oncology</i> , 2020, 7, 94-111.	0.3	2
9	Tumor-associated cytotoxic lymphocytes and macrophages as predictive factors in follicular lymphoma. <i>Biochemistry (Moscow) Supplement Series A: Membrane and Cell Biology</i> , 2014, 8, 198-205.	0.6	1
10	Complex cytogenetic research of cryptic chromosomal aberrations in patients with multiple myeloma. , 2019, 18, 50-59.	0.3	1
11	Thrombotic microangiopathy associated with hematopoietic stem cell transplantation: general characteristics and an example from clinical practice. <i>Russian Journal of Pediatric Hematology and Oncology</i> , 2020, 7, 86-93.	0.3	1